Cellectar Biosciences Inc.
CLRB | NASDAQ
$2.31
-$0.04 (-1.70%)
Sep 22, 2026, 11:16 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.35 | -0.25 | -0.79 | -0.38 | -1.52 | -2.73 |
PEG Ratio | 0 | 0 | 0.04 | -0.10 | 0.04 | 0.05 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 0.78 | 0.77 | -2.46 | 1.27 | 1.11 | 0.75 |
P/FCF Ratio | -0.33 | -0.23 | -1.02 | -0.47 | -1.61 | -2.94 |
P/OCF Ratio | -0.33 | -0.23 | -1.05 | -0.48 | -1.62 | -2.96 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.04 | 0.03 | -0.04 | 0.06 | 0.01 | 0.01 |
Quick Ratio | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 | 16.26 |
Current Ratio | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 | 16.26 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -219.69% | -311.87% | 310.45% | -333.42% | -73% | -27.55% |
Return on Assets | -145.48% | -175.01% | -354.19% | -147.26% | -64.84% | -25.73% |
Return on Invested Capital | -222.48% | -320.19% | 294.21% | -283.65% | -72.36% | -27.69% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove CLRB